CD79: a review.

CD79 is composed of CD79a and CD79b components expressed almost exclusively on B cells and B-cell neoplasms. CD79a and CD79b expression precedes immunoglobulin (Ig) heavy-chain gene rearrangement and CD20 expression during B-cell ontogeny and disappears later than CD20 in the late (plasma cell) stage of B-cell differentiation. Therefore, antibodies to CD79a and CD79b are useful in the differential diagnosis of B-cell neoplasms from T-cell neoplasms or myeloid neoplasms, or L and H lymphocyte predominance Hodgkin's lymphoma from classic Hodgkin's lymphoma. In addition, CD79a and CD79b antibodies are useful markers in the diagnosis of precursor B-acute lymphoblastic leukemia (pre-B-ALL) because many of these tumors are negative for other B-cell markers, such as CD20 and CD45RA. Furthermore, for B-cell neoplasms, wherein CD20 expression is aberrantly lost, such as in diffuse large B-cell lymphoma, or for B-cell neoplasms after CD20-antibody therapy, CD79a may be used as a first-line B-cell marker for the diagnosis. In this review, the authors discuss the molecular biology of CD79 and the frequency and usefulness of CD79 expression in these neoplasms.

[1]  K. Lennert,et al.  Reed-Sternberg and Hodgkin cells in lymphocyte-predominant Hodgkin's disease of nodular subtype contain J chain. , 1986, American journal of clinical pathology.

[2]  G. Pinkus,et al.  Hodgkin's disease, lymphocyte predominance type, nodular--further evidence for a B cell derivation. L & H variants of Reed-Sternberg cells express L26, a pan B cell marker. , 1988, The American journal of pathology.

[3]  M. Reth,et al.  Molecular components of the B-cell antigen receptor complex of the IgM class , 1990, Nature.

[4]  R. Kelly,et al.  Tyrosine phosphorylation of components of the B-cell antigen receptors following receptor crosslinking. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Mason,et al.  The membrane IgM-associated heterodimer on human B cells is a newly defined B cell antigen that contains the protein product of the mb-1 gene. , 1991, Journal of immunology.

[6]  J. V. van Dongen,et al.  The IgM-associated protein mb-1 as a marker of normal and neoplastic B cells. , 1991, Journal of immunology.

[7]  H. Nielsen,et al.  Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. , 1991 .

[8]  M. Cooper,et al.  Heterogeneity of immunoglobulin-associated molecules on human B cells identified by monoclonal antibodies. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[9]  J. Lin,et al.  The MB-1/B29 heterodimer couples the B cell antigen receptor to multiple src family protein tyrosine kinases. , 1992, Journal of immunology.

[10]  D. Mason,et al.  The B29 and mb‐1 polypeptides are differentially expressed during human B cell differentiation , 1992, European journal of immunology.

[11]  R. Bende,et al.  Comparison of human B cell antigen receptor complexes: membrane- expressed forms of immunoglobulin (Ig)M, IgD, and IgG are associated with structurally related heterodimers , 1992, The Journal of experimental medicine.

[12]  H. Ha,et al.  Molecular cloning and expression pattern of a human gene homologous to the murine mb-1 gene. , 1992, Journal of immunology.

[13]  T W Chang,et al.  Human mb-1 gene: complete cDNA sequence and its expression in B cells bearing membrane Ig of various isotypes. , 1992, Journal of immunology.

[14]  C. Terhorst,et al.  Cloning and sequencing of the cDNA encoding the human homologue of the murine immunoglobulin‐associated protein B29 , 1992, European journal of immunology.

[15]  M. Neuberger,et al.  Antigen presentation by the B cell antigen receptor is driven by the α β sheath and occurs independently of its cytoplasmic tyrosines , 1993, Cell.

[16]  M. Neuberger,et al.  Antigen presentation by the B cell antigen receptor is driven by the alpha/beta sheath and occurs independently of its cytoplasmic tyrosines. , 1993, Cell.

[17]  R. Hardy,et al.  The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver , 1993, The Journal of experimental medicine.

[18]  J. V. van Dongen,et al.  Transcription and protein expression of mb-1 and B29 genes in human hematopoietic malignancies and cell lines. , 1993, Leukemia.

[19]  D. Mason,et al.  mb-1: a new marker for B-lineage lymphoblastic leukemia. , 1993, Blood.

[20]  A. A. Thompson,et al.  Isolation and chromosomal mapping of the human immunoglobulin-associated B29 gene (IGB). , 1993, Genomics.

[21]  K. Gatter,et al.  Expression of the Ig‐associated heterodimer (mb‐1 and B29) in Hodgkin's disease , 1993, Histopathology.

[22]  M. Reth,et al.  Differential signaling through the Ig‐α and Ig‐β components of the B cell antigen receptor , 1993 .

[23]  C. Pleiman.  Distinct p53/56^ and p59^ domains associate with nonphosphorylated and phosphorylated lgα. , 1994 .

[24]  B. Emanuel,et al.  Structure, chromosomal localization, and methylation pattern of the human mb-1 gene. , 1994, Journal of immunology.

[25]  P. Korkolopoulou,et al.  The expression of the B‐cell marker mb‐1 (CD79a) in Hodgkin's disease , 1994, Histopathology.

[26]  D. Catovsky,et al.  The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. , 1994, Leukemia & lymphoma.

[27]  J. Coligan,et al.  Isolation and chemical characterization of the human B29 and mb-1 proteins of the B cell antigen receptor complex. , 1994, Molecular immunology.

[28]  J. Jongstra,et al.  Distinct p53/56lyn and p59fyn domains associate with nonphosphorylated and phosphorylated Ig-alpha. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[29]  E. Jaffe,et al.  CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples. , 1995, Blood.

[30]  G. Cattoretti,et al.  Correlation between presence of clonal rearrangements of immunoglobulin heavy chain genes and B-cell antigen expression in Hodgkin's disease. , 1995, American journal of clinical pathology.

[31]  J. Borst,et al.  Assembly and intracellular transport of the human B cell antigen receptor complex. , 1995, International immunology.

[32]  J. Salamero,et al.  Role of B cell receptor Igα and Igβ subunits in MHC class II-restricted antigen presentation , 1995 .

[33]  J. Salamero,et al.  Role of B cell receptor Ig alpha and Ig beta subunits in MHC class II-restricted antigen presentation. , 1995, Immunity.

[34]  R. V. van Lier,et al.  Antigen receptor nonresponsiveness in chronic lymphocytic leukemia B cells. , 1995, Blood.

[35]  P. Isaacson,et al.  Follicular Hodgkin's disease. , 1995, The American journal of surgical pathology.

[36]  Reth Michael,et al.  The B-cell antigen receptor complex and co-receptors. , 1995 .

[37]  P. Gaulard,et al.  Discordant expression of immunoglobulin and its associated molecule mb-1/CD79a is frequently found in mediastinal large B cell lymphomas. , 1995, The American journal of pathology.

[38]  D. Arber,et al.  Paraffin section immunophenotyping of acute leukemias in bone marrow specimens. , 1996, American journal of clinical pathology.

[39]  D. Catovsky,et al.  Expression of the immunoglobulin-associated protein B29 in B cell disorders with the monoclonal antibody SN8 (CD79b). , 1996, Leukemia.

[40]  I A Astsaturov,et al.  Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia. , 1996, Leukemia.

[41]  R. Lenski,et al.  Punctuated Evolution Caused by Selection of Rare Beneficial Mutations , 1996, Science.

[42]  K. Rajewsky,et al.  Aberrant B Cell Development and Immune Response in Mice with a Compromised BCR Complex , 1996, Science.

[43]  Michel C. Nussenzweig,et al.  Regulation of an Early Developmental Checkpoint in the B Cell Pathway by Igβ , 1996, Science.

[44]  M. Slovak,et al.  CD79 alpha expression in acute myeloid leukemia. High frequency of expression in acute promyelocytic leukemia. , 1996, The American journal of pathology.

[45]  K. Ishihara,et al.  CD79 alpha/CD79 beta heterodimers are expressed on pro-B cell surfaces without associated mu heavy chain. , 1997, International immunology.

[46]  H. Kerl,et al.  Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. , 1997, The American journal of surgical pathology.

[47]  Tetsuya Nakamura,et al.  The Igα/Igβ Heterodimer on μ-Negative ProB Cells Is Competent for Transducing Signals to Induce Early B Cell Differentiation , 1997 .

[48]  R. Alsabeh,et al.  Immunophenotype of Reed-Sternberg and Hodgkin's cells in sequential biopsy specimens of Hodgkin's disease: a paraffin-section immunohistochemical study using the heat-induced epitope retrieval method. , 1997, American journal of clinical pathology.

[49]  D. Catovsky,et al.  Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). , 1997, American journal of clinical pathology.

[50]  B-cell antigen receptor-induced apoptosis requires both Ig alpha and Ig beta. , 1997, Blood.

[51]  K. Gatter,et al.  An immunohistochemical analysis of Reed-Sternberg-like cells in posttransplantation lymphoproliferative disorders: the possible pathogenetic relationship to Reed-Sternberg cells in Hodgkin's disease and Reed-Sternberg-like cells in non-Hodgkin's lymphomas and reactive conditions. , 1997, Human pathology.

[52]  B. Eisfelder,et al.  B-Cell Antigen Receptor–Induced Apoptosis Requires Both Igα and Igβ , 1997 .

[53]  A. A. Thompson,et al.  Aberrations of the B-cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia. , 1997, Blood.

[54]  C. Li,et al.  Useful panel of antibodies for the classification of acute leukemia by immunohistochemical methods in bone marrow trephine biopsy specimens. , 1997, American journal of clinical pathology.

[55]  S. Liebhaber,et al.  Physical linkage of the human growth hormone gene cluster and the CD79b (Ig beta/B29) gene. , 1998, Genomics.

[56]  H. Müller-Hermelink,et al.  Co‐expression of CD79a (JCB117) and CD3 by lymphoblastic lymphoma , 1998, The Journal of pathology.

[57]  Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny. , 1998 .

[58]  S. Pileri,et al.  Acute leukaemia immunophenotyping in bone‐marrow routine sections , 1999, British journal of haematology.

[59]  D. Czerwinski,et al.  Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  C. White,et al.  Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. , 1999, Seminars in oncology.

[61]  E. Kaiserling,et al.  Immunophenotyping of acute lymphoblastic leukaemia in routinely processed bone marrow biopsy specimens. , 1999, Journal of clinical pathology.

[62]  D. R. Anderson,et al.  Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. , 1999, International journal of oncology.

[63]  D. Campana,et al.  Mutations in Igα (CD79a) result in a complete block in B-cell development , 1999 .

[64]  E. Matutes,et al.  Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. , 1999, Haematologica.

[65]  P. Circosta,et al.  An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia. , 1999, Blood.

[66]  O. Press.  Radiolabeled antibody therapy of B-cell lymphomas. , 1999, Seminars in oncology.

[67]  Paul J. Kurtin,et al.  Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry. , 1999, American journal of clinical pathology.

[68]  L. Benito,et al.  CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection , 1999, Leukemia.

[69]  Harris,et al.  Extra‐medullary myeloid tumour (granulocytic sarcoma) is often misdiagnosed: a study of 26 cases , 1999, Histopathology.

[70]  A. A. Thompson,et al.  Widespread B29 (CD79b) gene defects and loss of expression in chronic lymphocytic leukemia. , 1999, Leukemia & lymphoma.

[71]  W. Jurecka,et al.  Immunoreactivity of B-Cell Markers (CD79a, L26) in Rare Cases of Extranodal Cytotoxic Peripheral T- (NK/T-) Cell Lymphomas , 2000, Modern Pathology.

[72]  P. Musto,et al.  CD79b expression in B-cell chronic lymphocytic leukemia. , 2000, Haematologica.

[73]  J. Wienands,et al.  The B-cell antigen receptor: formation of signaling complexes and the function of adaptor proteins. , 2000, Current topics in microbiology and immunology.

[74]  J. Juco,et al.  Flow cytometric detection of CD79a expression in T-cell acute lymphoblastic leukemias. , 2000, American journal of clinical pathology.

[75]  Miller,et al.  The diagnosis of low‐grade peripheral B‐cell neoplasms in bone marrow trephines , 2000, British journal of haematology.

[76]  L. Medeiros,et al.  Sinusoidal CD30-Positive Large B-Cell Lymphoma: A Morphologic Mimic of Anaplastic Large Cell Lymphoma , 2000, Modern Pathology.

[77]  Yamashita,et al.  Varied B‐cell immunophenotypes of Hodgkin/Reed–Sternberg cells in classic Hodgkin's disease , 2000, Histopathology.